Pope JE, et al. State-of-the-art evidence in the treatment of SSc. Nat Rev Rheumatol. 2023;19(4):212–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Low AHL, et al. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma. Int J Rheum Dis. 2019;22(6):1036–40.

Article  PubMed  PubMed Central  Google Scholar 

Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous SSc: an unmet clinical need. Nat Rev Rheumatol. 2022;18(5):276–85.

Article  PubMed  PubMed Central  Google Scholar 

Khanna D, et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous SSc. Arthritis Rheumatol. 2016;68(2):299–311.

Article  PubMed  PubMed Central  Google Scholar 

Khanna D, et al. New composite endpoint in early diffuse cutaneous SSc: revisiting the provisional American College of Rheumatology Composite Response Index in SSc. Ann Rheum Dis. 2021;80(5):641–50.

Article  PubMed  Google Scholar 

Mulcaire-Jones E, et al. Advances in biological and targeted therapies for SSc. Expert Opin Biol Ther. 2023;23(4):325–39.

Article  CAS  PubMed  Google Scholar 

Di Battista M, et al. SSc: one year in review 2023. Clin Exp Rheumatol. 2023;41(8):1567–74.

Pellar RE, Pope JE. Evidence-based management of SSc: navigating recommendations and guidelines. Semin Arthritis Rheum. 2017;46(6):767–74.

Article  PubMed  Google Scholar 

Denton CP, et al. BSR and BHPR guideline for the treatment of SSc. Rheumatology (Oxford). 2016;55(10):1906–10.

Article  PubMed  Google Scholar 

Kowal-Bielecka O, et al. Update of EULAR recommendations for the treatment of SSc. Ann Rheum Dis. 2017;76(8):1327–39.

Article  PubMed  Google Scholar 

Fernandez-Codina A, et al. Treatment algorithms for SSc according to experts. Arthritis Rheumatol. 2018;70(11):1820–8.

Article  CAS  PubMed  Google Scholar 

van den Hoogen FH, et al. Comparison of methotrexate with placebo in the treatment of SSc: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–72.

Article  PubMed  Google Scholar 

Pope JE, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–8.

Article  CAS  PubMed  Google Scholar 

Namas R, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res (Hoboken). 2018;70(3):439–44.

Article  CAS  PubMed  Google Scholar 

Tashkin DP, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tashkin DP, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.

Article  CAS  PubMed  Google Scholar 

Yoshifuji H, et al. Role of rituximab in the treatment of SSc: a literature review. Mod Rheumatol. 2023;33(6):1068–77.

Sullivan KM, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35–47.

Article  PubMed  PubMed Central  Google Scholar 

van Bijnen S, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for SSc: results of a long-term follow-up multicentre study. Ann Rheum Dis. 2020;79(8):1084–9.

Article  PubMed  Google Scholar 

van Laar JM, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous SSc: a randomized clinical trial. JAMA. 2014;311(24):2490–8.

Article  PubMed  Google Scholar 

Herrick AL, et al. Treatment outcome in early diffuse cutaneous SSc: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207–18.

Article  CAS  PubMed  Google Scholar 

Bruera S, et al. Stem cell transplantation for SSc. Cochrane Database Syst Rev. 2022;7(7):CD011819.

PubMed  Google Scholar 

Burt RK, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for SSc (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498–506.

Article  CAS  PubMed  Google Scholar 

Wollin L, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Distler O, et al. Nintedanib for SSc-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28.

Article  CAS  PubMed  Google Scholar 

Khanna D, et al. Safety and efficacy of subcutaneous tocilizumab in adults with SSc (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–40.

Article  CAS  PubMed  Google Scholar 

Khanna D, et al. Tocilizumab in SSc: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–74.

Article  CAS  PubMed  Google Scholar 

Khanna D, et al. Abatacept in early diffuse cutaneous SSc: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol. 2020;72(1):125–36.

Article  CAS  PubMed  Google Scholar 

Domsic RT, et al. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. Rheumatology (Oxford). 2023;62(4):1543–51.

Article  PubMed  Google Scholar 

Moriana C, et al. JAK inhibitors and SSc: a systematic review of the literature. Autoimmun Rev. 2022;21(10):103168.

Article  CAS  PubMed  Google Scholar 

Khanna D, et al. Riociguat in patients with early diffuse cutaneous SSc (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. 2020;79(5):618–25.

Article  PubMed  Google Scholar 

Giorgi V, et al. Cannabis and autoimmunity: possible mechanisms of action. Immunotargets Ther. 2021;10:261–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spiera R, et al. Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous SSc. Arthritis Rheumatol. 2023;75(9):1608–18.

Allanore Y, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous SSc. Ann Rheum Dis. 2020;79(12):1600–7.

Article  CAS  PubMed  Google Scholar 

Khanna D, et al. A 24-week, phase IIa, randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous SSc. Arthritis Rheumatol. 2023;75(8):1434–44.

Rice LM, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in SSc patients. J Clin Invest. 2015;125(7):2795–807.

Article  PubMed  PubMed Central  Google Scholar 

Fukasawa T, et al. Interleukin-17 pathway inhibition with brodalumab in early SSc: analysis of a single-arm, open-label, phase 1 trial. J Am Acad Dermatol. 2023;89(2):366–9.

Article  CAS  PubMed  Google Scholar 

Guo X, et al. Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with SSc. J Invest Dermatol. 2015;135(10):2402–9.

Article  CAS  PubMed  Google Scholar 

Bergmann C, et al. Treatment of a patient with severe SSc (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117–20.

Article  MathSciNet  PubMed  Google Scholar 

Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin N Am. 2002;28(3):603–24.

Article  Google Scholar 

Peterson LS, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80.

CAS  PubMed  Google Scholar 

Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28 (quiz 229–230).

Article  PubMed  Google Scholar 

Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13.